The drug mirvetuximab soravtansin increased the survival rate of women with ovarian cancer. Additionally, three times more patients were sensitive to mirvetuximab compared to chemotherapy. The research was published in the journal NEJM.
Ovarian cancer is one of the most dangerous tumors, with low survival rates and limited treatment options.
In a Phase 3 clinical trial, researchers compared the effectiveness and safety of mirvetuximab soravtansine (MIRV) and chemotherapy in the treatment of platinum-resistant high-grade ovarian cancer. Before the study, more than 450 participants received one to three types of therapy.
Chemotherapy drugs used in the new trial included paclitaxel, pegylated liposomal doxorubicin and topotecan. All were less effective than MIRV: the median time without tumor progression was 3.98 and 5.62 months, respectively. Additionally, 15.9% of participants in the chemotherapy group and 42.3% of participants in the new drug group responded to the treatment.
Overall survival was 12.75 months with chemotherapy and 16.46 months with mirvetuximab soravtansin.
The new drug also caused fewer serious side effects.
The study was funded by ImmunoGen, which developed MIRV.
Previous scientists I learnedHow can you reduce your risk of breast cancer by 55%?